ADVA unveils commercially ready disaggregated cell site gateway solution at TIP ’19
13.11.2019 15:15:00 EET | Business Wire | Press release
ADVA (FSE: ADV) today announced the commercial readiness of its disaggregated cell site gateway (DCSG) solution at the Telecom Infra Project (TIP) Summit. Powered by ADVA’s Ensemble Activator network operating system (NOS), the integrated white box solution comes with a comprehensive bundle of installation, commissioning and monitoring services for rapid network deployment. The technology is currently on display in a 5G demo at the TIP Summit with ADVA’s software running on Edgecore’s new family of DCSG devices. The showcase highlights how mobile network operators (MNOs) now have an easy and cost-effective route to mass small cell deployment for 5G services. Already successful in a series of trials in global MNO networks, Ensemble Activator is the industry’s only true carrier-grade NOS for bare-metal switches.
“This is a landmark moment for mobile networks. Now that MNOs can leverage our DCSG solution as a simple and complete answer for evolving their infrastructure to 5G, the shackles are off. We’re empowering them to roll out widespread small cell networks in a way that’s simple, affordable and future-proof. Our technology and complete service bundle make the transition easy so that MNOs are free to focus instead on the business opportunities that 5G offers,” said Eli Angel, VP, product line management, Ethernet access, ADVA. “This TIP demo also highlights the value of openness and disaggregation in mobile networks. By enabling software to be separated from hardware, we’re giving operators the freedom to select the ideal technology combination for their needs and harness the latest and greatest innovation.”
The new DCSG solution has been engineered to TIP’s white box gateway specifications. By giving MNOs the power to move away from a closed proprietary system to an open, disaggregated and vendor-neutral infrastructure, it provides the opportunity to massively increase network efficiencies. What’s more, the new DCSG technology enables an open approach, accelerating innovation cycles and reducing CAPEX. As well as providing a NOS, protocol support, dynamic configurability, and manageability, the DCSG solution also delivers IEEE 1588 timing with optional SFP-based GNSS backup. Powered by Ensemble Activator, the DCSG technology is the second commercial offering ADVA has developed for TIP, following its successful rollout of a packet optical solution built around the Voyager optical white box.
“It’s great to see how rapidly this community has produced results. After only 12 months, our initiative has pushed DCSG technology from concept to reality and created a solution ready for deployment in live networks. With ADVA’s Ensemble Activator becoming generally available, operators have a clear roadmap to the next generation of mobile networks,” commented Luis MartinGarcia, co-lead, DCSG project group, TIP. “MNOs can now harness a complete and fully tested DCSG solution that enables them to address today’s key challenges. It opens the door to the deployment of the hundreds of thousands of cell site gateways needed to address the mobile backhaul demands of 5G.”
“What we’re presenting to the industry here at TIP ’19 is a new and innovative method of building and deploying telecom networks. We’re showcasing a way to tackle the most pressing challenges of 4G and emerging 5G mobile networks by enabling open technology choices and delivering the cost-efficiency of disaggregation. ADVA’s Ensemble Activator running on our cell site gateway family of products offers the ultimate route to lower costs and increased service flexibility,” said Matt Roman, VP, marketing and product management, Edgecore. ”The rapid success of this project is due to the close collaboration of our teams. Working together with ADVA, we’ve built an integrated technology which, when coupled with a rich set of supporting services, enables MNOs to utilize a truly cohesive open cell site solution.”
ADVA’s new DCSG solution will be on display at the TIP Summit’s LiveLab from November 13 to 14.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191113005408/en/
Contact information
For ADVA press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For ADVA investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom